… was to clinically evaluate circulating tumor DNA (ctDNA) with a … Subjects and Methods: DNA
from 1059 asymptomatic subjects … Analysis of buffy coat DNA from eight positive subjects, …

… For the use of ctDNA assays in other settings, such as detection of residual disease following
treatment for primary cancers or detection of tumors in screening asymptomatic individuals, …

… asymptomatic, average-risk adults, based on a critical review of existing guidelines and
their evidence reviews. This guidance statement does not address surveillance in patients with …

… be useful as molecular markers for detecting tumor DNA in different bodily fluids. In patients
… of non-cell-bound DNA. In this free circulating DNA, tumor-associated molecular alterations …

The development of new circulating-tumor DNA (ctDNA) analysis techniques has led to an
explosion of studies demonstrating exciting clinical applications. Non-invasive genotyping …

… -based, multitarget DNA panel with Hemoccult II in asymptomatic adults, 50 years of … DNA
as the analyte is that a marker panel can be expanded or refined as knowledge about tumor …

PURPOSE Earlier detection of cancer recurrence using circulating tumor DNA (ctDNA) to
detect molecular residual disease (MRD) has the potential to dramatically affect cancer …

… Like proteins, tumor DNA also can be released into the circulation. Such circulating tumor
DNA (ctDNA) can be differentiated from … Sensitivity is likely to be less in asymptomatic subjects …

… The following search terms were used: ctDNA OR circulating tumor DNA OR liquid biopsy
AND breast cancer OR breast carcinoma OR breast tumor AND prognosis OR survival. All …

… of asymptomatic disease for these tumors, which often progress rapidly and typically manifest
as advanced. In addition, the low-dose, nonenhanced technique utilized for screening CT …